纳米载体
肝细胞癌
医学
药物输送
药品
靶向给药
癌症研究
肝癌
癌症
化学
纳米医学
纳米技术
计算生物学
索拉非尼
作者
Abdulsalam Alhalmi,Sarwar Beg,Kanchan Kohli,Md. Waris,Tanuja Singh
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2021-01-01
卷期号:22 (7): 779-792
被引量:5
标识
DOI:10.2174/1389450121999201209194524
摘要
Hepatocellular carcinoma (HCC) is the primary liver cancer that has shown a high incidence and mortality rate worldwide among several types of cancers. A large variety of chemotherapeutic agents employed for the treatment have a limited success rate owing to their limited site-specific drug targeting ability. Thus, there is a demand to develop novel approaches for the treatment of HCC. With advancements in nanotechnology-based drug delivery approaches, the challenges of conventional chemotherapy have been continuously decreasing. Nanomedicines constituted of lipidic and polymeric composites provide a better platform for delivering and opening new pathways for HCC treatment. A score of nanocarriers such as surface-engineered liposomes, nanoparticles, nanotubes, micelles, quantum dots, etc., has been investigated in the treatment of HCC. These nanocarriers are considered to be highly effective clinically for delivering chemotherapeutic drugs with high site-specificity ability and therapeutic efficiency. The present review highlights the current focus on the application of nanocarrier systems using various ligand-based receptor-specific targeting strategies for the treatment and management of HCC. Moreover, the article has also included information on the current clinically approved drug therapy for hepatocellular carcinoma treatment and updates of regulatory requirements for approval of such nanomedicines.
科研通智能强力驱动
Strongly Powered by AbleSci AI